evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,497 questions · 1,590 findings · 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 281 · 17.7%GRADE not reported 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%

Low molecular weight heparin vs no LMWH

Antibiotic versus heparin only lock/flush solution: catheter‐related infections · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in catheter‐related infection (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Major bleeding · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Minor bleeding · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

All‐cause mortality · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Recurrent VTE · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis may leads to lower recurrent VTE compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major bleeding · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major GI bleeding · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major GI bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major upper GI bleeding · patients with cancer with venous thromboembolism

It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major lower GI bleeding · patients with cancer with venous thromboembolism

It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major lower GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major non‐GI bleeding · patients with cancer with venous thromboembolism

It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Minor bleeding · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis probably leads to higher minor bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Minor GI bleeding · patients with cancer with venous thromboembolism

It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Minor upper GI bleeding · patients with cancer with venous thromboembolism

It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Minor lower GI bleeding · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor lower GI bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review